Document is current
Any future updates will be listed below
-
Authors
Isley, Serena
Johnson, Emily https://orcid.org/0000-0002-3419-8372
Swain, Mark G.
Tandon, Puneeta https://orcid.org/0000-0003-0486-0174
- License Information
-
More Information
Article History
Accepted: 16 September 2025
First Online: 20 October 2025
Declarations
:
: Not applicable.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: Mark G. Swain serves in an advisory role for Gilead, Ipsen, Novo Nordisk, Advanz, Abbott, GSK, Mirum, and Boehringer Ingelheim; is a speaker for IPSEN and Gilead; has received clinical trial funding from Gilead, GSK, Cymabay, Intercept, Kowa, Novo Nordisk, Pfizer, Ancella, Merck, Galectin, Ipsen, Madrigal, Roche, Altimmune, 89Bio, Inventiva, Boehringer Ingelheim. Puneeta Tandon serves in an advisory role for Gilead and Ipsen.
